This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy to Treat Non-Small Cell Lung Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Luhua Wang, Chinese Academy of Medical Sciences
ClinicalTrials.gov Identifier:
NCT01494558
First received: December 14, 2011
Last updated: December 16, 2011
Last verified: December 2011
  Purpose
Cisplatin-based combination chemotherapy given concurrently with radiotherapy is the standard of care for patients with inoperable stage III NSCLC. The most common chemotherapeutic agents used concurrently with radiotherapy have been vinorelbine, vinblastine, and etoposide in conjunction with cisplatin or weekly paclitaxel and carboplatin. No randomized phase III trials of concurrent chemoradiotherapy have shown the superiority of one chemotherapy regimen over another. The clinical trial is to compare radiotherapy concurrently with PE (etoposide and cisplatin) and PC (paclitaxel and carbplatin) for local advanced NSCLC (stage IIIA/IIIB). It is a randomized, multicenter, open labeled phase III clinical trial. All patients receive conformal radiotherapy or intensity modulated radiotherapy with conventional fraction. The chemotherapy regimens are PE (etoposide 50mg/m2 d1-5, 29-33 and cisplatin 50mg/m2 d1,8,29 and 36 29-33 ) and PC (paclitaxel 45mg/m2 weekly over 1hour and carbplatin AUC =2mg/mL/min over 30min weekly). The primary purpose is to evaluate objective response rate, complications, progression-free survival, overall survival. The second purpose is to evaluate quality of life and cost.

Condition Intervention Phase
Non-Small Cell Lung Cancer Other: Chemoradiotherapy Regimen between PC and PE Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 3 Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy in Patients With Unresectable Locally Advanced, Stage III Non-Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Luhua Wang, Chinese Academy of Medical Sciences:

Primary Outcome Measures:
  • Overall Survival [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Progression Free Survival [ Time Frame: 2 years ]

Enrollment: 200
Study Start Date: May 2007
Study Completion Date: August 2011
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: PE concurrent chemotherapy
Radiotherapy concurrently with PE chemotherapy
Other: Chemoradiotherapy Regimen between PC and PE
etoposide 50mg/m2 d1-5, 29-33 and cisplatin 50mg/m2 d1,8,29 and 36 29-33 during radiotherapy paclitaxel 45mg/m2 weekly and carbplatin AUC =2mg/mL/min weekly during radiotherapy
Other Name: Chemoradiotherapy
Active Comparator: PC concurrent chemotherapy
Radiotherapy concurrently with PC chemotherapy
Other: Chemoradiotherapy Regimen between PC and PE
etoposide 50mg/m2 d1-5, 29-33 and cisplatin 50mg/m2 d1,8,29 and 36 29-33 during radiotherapy paclitaxel 45mg/m2 weekly and carbplatin AUC =2mg/mL/min weekly during radiotherapy
Other Name: Chemoradiotherapy

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Inoperable stage IIIA/IIIB NSCLC proved by pathology or cytology
  2. Age 18 to 75, ECOG ≤ 2, lose weight <10% during 6 months
  3. No serious diseases of important organs
  4. Chest CT in recently 4 weeks
  5. No other tumor disease except stage I cervical cancer or cutaneous basal cell carcinoma
  6. Sign consent
  7. Measurable lesion

Exclusion Criteria:

  1. Pretreatment radiotherapy or chemotherapy
  2. Pregnant or lactation woman
  3. Serious diseases (include uncontrolled diabetes and infection) of important organs
  4. Psychopath
  5. Join in other clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01494558

Sponsors and Collaborators
Chinese Academy of Medical Sciences
Investigators
Principal Investigator: luhua Wang, MD Department of Radiation Oncology, Cancer Hospital & Institution, CAMS & PUMC
  More Information

Responsible Party: Luhua Wang, Chairman of Thoracic Group, Clinical Professor, Radiation Oncology Department, Cancer Hospital&Institute, Chinese Academy of Medical Sciences
ClinicalTrials.gov Identifier: NCT01494558     History of Changes
Other Study ID Numbers: 2006BAI02A02[1]-03
Study First Received: December 14, 2011
Last Updated: December 16, 2011

Keywords provided by Luhua Wang, Chinese Academy of Medical Sciences:
Overall survival

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Paclitaxel
Etoposide
Etoposide phosphate
Albumin-Bound Paclitaxel
Cisplatin
Carboplatin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on July 21, 2017